TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - H. LUNDBECK B Share Price

Certificat

DE000SQ2GVA8

Delayed Deutsche Boerse AG 19:50:33 27/06/2024 BST
1.76 EUR +0.57% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - H. LUNDBECK B
Current month-0.57%
1 month+6.06%
Date Price Change
27/06/24 1.76 +0.57%
26/06/24 1.75 -4.37%
25/06/24 1.83 +2.23%
24/06/24 1.79 -3.24%
21/06/24 1.85 +1.65%

Delayed Quote Deutsche Boerse AG

Last update June 27, 2024 at 07:50 pm

More quotes

Static data

Product typeKnock-Out sin Stop Loss
Buy / SellCALL
Underlying H. LUNDBECK A/S
IssuerLogo Issuer Société Générale Société Générale
WKN SQ2GVA
ISINDE000SQ2GVA8
Date issued 05/10/2022
Strike 25.03 kr
Maturity Unlimited
Parity 1 : 1
Emission price 0.27
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.21
Lowest since issue 0.17
Spread 0.03
Spread %1.68%

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
-
More about the company

Ratings for H. Lundbeck A/S

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: H. Lundbeck A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
38.02 DKK
Average target price
39.96 DKK
Spread / Average Target
+5.10%
Consensus